Showing results for "#Bharat Biotech"
Over 30% Covaxin takers suffered from health issues after 1 year,...
Nearly 50 per cent of 926 study participants in the study complained of infections during the follow-up period, predominated by viral upper...
Seven Indian pharma players race to develop vaccine for COVID-19
At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they join global efforts to find a preventive to check...
Bharat Biotech inks pact with WU's School of Medicine for COVID-19...
Bharat Biotech on Wednesday signed a licensing agreement with Washington University School of Medicine in St Louis, US for a novel "chimp-adenovirus",...
Covaxin phase three trial to start next month
With the first two phases not throwing up any adverse effects, the phase three trial of Bharat Biotech’s COVID-19 vaccine, Covaxin, is likely to start...
India’s COVID vaccines in race to go global
Bharat Biotech is in discussions with more than 10 countries that have shown an interest in a potential COVID-19 vaccine it is developing with a...
No major adverse events in 2 phases of Covaxin trials: Bharat Biotech
"The Phase III efficacy data will be available approximately at the end of Q1 in 2021, after which we will apply for regulatory approval for release...
Vaccinating 130Cr people with injectable Covaxin a challenge: Bharat...
Bharat Biotech International Limited (BBIL) Chairman and Managing Director Krishna Ella said the company's Bio-Safety Level 3 (BSL-3) facility...
Bharat Biotech seeks emergency use nod for Covid vaccine
Covaxin has been evaluated in 1,000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity data.
